Leap Therapeutics, Inc. (LPTX): Price and Financial Metrics

Leap Therapeutics, Inc. (LPTX): $1.71

-0.05 (-2.84%)

POWR Rating

Component Grades













Add LPTX to Watchlist
Sign Up

Industry: Biotech


of 450

in industry


  • Value is the dimension where LPTX ranks best; there it ranks ahead of 39.42% of US stocks.
  • The strongest trend for LPTX is in Value, which has been heading down over the past 169 days.
  • LPTX's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks).

LPTX Stock Summary

  • For LPTX, its debt to operating expenses ratio is greater than that reported by just 0.39% of US equities we're observing.
  • LPTX's price/sales ratio is 103.63; that's higher than the P/S ratio of 97.63% of US stocks.
  • With a year-over-year growth in debt of -100%, Leap Therapeutics Inc's debt growth rate surpasses only 0% of about US stocks.
  • Stocks that are quantitatively similar to LPTX, based on their financial statements, market capitalization, and price volatility, are MGNX, PLRX, SQZ, ABUS, and JNCE.
  • LPTX's SEC filings can be seen here. And to visit Leap Therapeutics Inc's official web site, go to www.leaptx.com.

LPTX Valuation Summary

  • In comparison to the median Healthcare stock, LPTX's price/sales ratio is 1700% higher, now standing at 68.4.
  • LPTX's EV/EBIT ratio has moved up 0.5 over the prior 56 months.
  • LPTX's price/earnings ratio has moved up 0.3 over the prior 56 months.

Below are key valuation metrics over time for LPTX.

Stock Date P/S P/B P/E EV/EBIT
LPTX 2021-08-31 68.4 3.4 -3.2 -2.0
LPTX 2021-08-30 68.2 3.4 -3.2 -2.0
LPTX 2021-08-27 69.6 3.5 -3.2 -2.1
LPTX 2021-08-26 69.2 3.5 -3.2 -2.1
LPTX 2021-08-25 71.2 3.6 -3.3 -2.2
LPTX 2021-08-24 72.4 3.6 -3.3 -2.2

LPTX Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -34.48%.
  • Its 4 year net cashflow from operations growth rate is now at 5.43%.
  • Its 4 year net income to common stockholders growth rate is now at -62.3%.
Over the past 27 months, LPTX's revenue has gone up $1,500,000.

The table below shows LPTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 1.5 -30.429 -36.509
2021-06-30 1.5 -28.919 -32.427
2021-03-31 1.5 -30.618 -29.417
2020-12-31 1.5 -25.957 -37.588
2020-09-30 1.125 -25.863 -38.874
2020-06-30 0.75 -26.228 -39.752

LPTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LPTX has a Quality Grade of D, ranking ahead of 18.21% of graded US stocks.
  • LPTX's asset turnover comes in at 0.03 -- ranking 351st of 682 Pharmaceutical Products stocks.
  • LNTH, ADMP, and CASI are the stocks whose asset turnover ratios are most correlated with LPTX.

The table below shows LPTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.030 1 5.490
2021-03-31 0.026 1 5.491
2020-12-31 0.028 1 5.014
2020-09-30 0.027 1 5.353
2020-06-30 0.025 1 5.974
2020-03-31 0.021 1 6.796

LPTX Price Target

For more insight on analysts targets of LPTX, see our LPTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.10 Average Broker Recommendation 1.4 (Strong Buy)

LPTX Stock Price Chart Interactive Chart >

Price chart for LPTX

LPTX Price/Volume Stats

Current price $1.71 52-week high $4.17
Prev. close $1.76 52-week low $1.33
Day low $1.65 Volume 2,081,000
Day high $1.76 Avg. volume 2,551,105
50-day MA $2.61 Dividend yield N/A
200-day MA $2.18 Market Cap 151.02M

Leap Therapeutics, Inc. (LPTX) Company Bio

Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in acquiring and developing therapeutics in cancer biology. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.

LPTX Latest News Stream

Event/Time News Detail
Loading, please wait...

LPTX Latest Social Stream

Loading social stream, please wait...

View Full LPTX Social Stream

Latest LPTX News From Around the Web

Below are the latest news stories about Leap Therapeutics Inc that investors may wish to consider to help them evaluate LPTX as an investment opportunity.

Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, and Cynthia Sirard, MD, Chief Medical Officer, will present a corporate overview at the B. Riley Securities Oncology Investor Conference. The conference will be held in a virtual meeting format.

Yahoo | January 24, 2022

Community Trust & Investment Co Buys Cheniere Energy Inc, Salesforce. ...

Lexington, KY, based Investment company Community Trust & Investment Co (Current Portfolio) buys Cheniere Energy Inc, Salesforce.com Inc, PayPal Holdings Inc, AstraZeneca PLC, The Walt Disney Co, sells Southwest Airlines Co, Lowe's Inc, Nike Inc, Norfolk Southern Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Community Trust & Investment Co.

Yahoo | January 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | January 19, 2022

Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients

Leap Therapeutics Inc (NASDAQ: LPTX ) will present updated data from the DisTinGuish Phase 2a study of DKN-01 , in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer (G/GEJ). Data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Tislelizumab is BeiGene Ltd''s (NASDAQ: BGNE ) anti-PD-1 antibody. In first-line patients treated with DKN-01 combo therapy showed overall preliminary median progression-free survival (PFS) of 10.7 months. The Full story available on Benzinga.com

Benzinga | January 19, 2022

Why Leap Therapeutics Stock Is Surging Today

Positive clinical trial results are giving investors a reason to cheer.

The Motley Fool | January 19, 2022

Read More 'LPTX' Stories Here

LPTX Price Returns

1-mo -46.73%
3-mo -38.71%
6-mo 6.21%
1-year -26.61%
3-year -21.38%
5-year -76.58%
YTD -47.22%
2021 44.00%
2020 100.89%
2019 -44.00%
2018 -67.95%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8225 seconds.